To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
A First-in-Class Approach to FcRn
ARGX-118 was designed as a highly differentiated antibody against Galectin-10, the protein of Charcot-Leyden crystals (CLCs), which are implicated as a major contributor to airway inflammation and the persistence of mucus plugs.
Current argenx Pipeline Progress
No results
Case Study
ARGX-118 was built in collaboration with Prof. Bart Lambrecht, M.D., Ph.D., who identified the first novel airway inflammation target in decades. For more info on this Case Study, click the link below.
Mechanism of Action
ARGX-118 is designed to bind to an epitope of Galectin-10 that is critical for crystal packing. It not only prevents Galectin-10 crystallization, but also rapidly solubilizes CLCs.
CLCs are frequently observed in the mucus of patients with eosinophilic respiratory diseases and promote type 2 immunity and mucus plugging. By nebulization of ARGX-118, argenx aims to improve the viscoelasticity of mucus.
Publications
Explore the peer-reviewed publications behind the clinical development and outcomes of ARGX-118 and more in long-overlooked diseases.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Efgartigimod
The science and data behind our first-in-class FcRn-targeting antibody for severe autoimmune diseases.
Empasiprubart
Engineered to block complement activation at C2, with potential across multiple severe autoimmune disease indications.
Partnered Program Success
See how IIP-born assets move forward with the right partners.
